Sumatriptan (brand names “Imitrex”) is a synthetic medication that was initially approved in 1991 for the treatment of migraine and cluster headaches. Chemically, it is classified as a “triptan” or tryptamine-based agent and is identified as a structural analogue of various alkaloids such as bufotenine and DMT (dimethyltryptamine). When administered following the onset of a …
Fioricet is a medication approved by the FDA for the treatment of three specific types of headaches including: tension, muscle contraction, and post-dural puncture. It contains a unique blend of a barbiturate (butalbital 50 mg), a pain reliever (acetaminophen 300 mg), and a stimulant (caffeine 40 mg); hence the reason it is sometimes abbreviated as Butal-Acet-Caff. …
Fioricet is a brand name medication comprised of the following ingredients: butalbital (50 mg), acetaminophen (300 mg), and caffeine (40 mg). The combination of a barbiturate (butalbital), a nonsteroidal anti-inflammatory drug (acetaminophen), and central nervous system stimulant (caffeine) – seem to act synergistically to alleviate various types of headaches. Medically, Fioricet is approved by the …
Minocycline is a broad-spectrum antibiotic of the tetracycline classification, indicating that its chemical structure consists of 4 hydrocarbon rings. The fact that minocycline has a broad-spectrum mechanism indicates that it targets a wide-range of pathogenic (Gram-positive and Gram-negative) bacteria. In fact, when compared to other tetracycline drugs, minocycline is regarded as having the “broadest spectrum” …
Cannabidiol (CBD) is just one of over 85 scientifically-identified cannabinoids (or chemical compounds) derived from the flowering plant cannabis. Each of the cannabinoids within cannabis elicit unique neurophysiological effects. Most people are well-aware of THC (tetrahydrocannabinol), the predominant cannabinoid within cannabis that is ingested by upwards of 230 million people per year as a psychoactive …
Sinemet is a pharmaceutical drug engineered by Merck that combines Carbidopa (a peripheral enzymatic inhibitor of DOPA decarboxylase) and Levodopa (an agent that crosses the blood-brain barrier to increase central concentrations of dopamine); hence it is frequently referred to as “Carbidopa-Levodopa.” The drug was initially approved by the U.S. FDA in 1988 for the treatment …
Requip (Ropinirole) is a drug initially approved in 1997 by the United States FDA for the treatment of [early or advanced-stage] idiopathic Parkinson’s disease. In the management of Parkinson’s disease, Requip can be utilized either as: a standalone agent or as an adjunct to L-DOPA. After its initial approval for the attenuation of Parkinson’s symptoms, …